Exelixis Announces Initiation of the STELLAR-303 Phase 3 …
https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-initiation-stellar-303-phase-3-pivotal-trial
WEBJun 21, 2022 · ALAMEDA, Calif. -- (BUSINESS WIRE)--Jun. 21, 2022-- Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-303, a phase 3 pivotal trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer (CRC) that is not microsatellite instability-high or mismatch …
DA: 78 PA: 45 MOZ Rank: 2